Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/s
The Supreme Court ruled that a generic drug company can force a brand-name manufacturer to correct an inaccurate description of its patent's scope, called a use code, when that description wrongly blocks the generic version from reaching the market for uses the patent doesn't actually cover.
The decision closes a loophole that let brand manufacturers write overly broad patent descriptions to delay cheaper generic competitors, giving generic companies a real tool to challenge those descriptions in court rather than waiting out lengthy patent litigation.
How it got here: A federal trial court sided with Caraco, but the Federal Circuit reversed, ruling Caraco had no legal basis for its counterclaim; the Supreme Court then agreed to hear the case.
The Case in Depth
What happened
Novo Nordisk sells Prandin, a brand-name diabetes drug with three FDA-approved uses, but its patent covers only one of those uses (combined with metformin). Caraco wanted to sell a generic version of the drug for the other two uses. After Caraco proposed a label excluding the patented use, Novo changed its patent description to make it appear the patent covered all three uses, blocking Caraco's plan.
The question before the Court
Could a generic drugmaker sue a brand-name drugmaker to fix a government filing that wrongly claimed patent protection over uses of a drug the generic company wanted to sell?
The Court's answer
Yes — the Supreme Court ruled that a generic drug company can use this counterclaim to force a brand-name manufacturer to correct an inaccurate use code, even when the brand's patent validly covers one approved use, so long as the patent doesn't cover the specific use the generic company wants to sell. The Court rejected the brand's argument that the challenge is only available when the patent covers no approved use whatsoever.
The Court reasoned that the law's overall design already lets generic drugs reach the market for unpatented uses while a brand's patent still covers a different use, so the challenge should match that same principle. The Court also pointed out that the remedy of "correcting" a listing (as opposed to simply deleting it) only makes sense if the challenge can apply to use codes that inaccurately describe patents that do cover something, not just nonexistent patents.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Generic drug companies gain a concrete legal tool to challenge brand manufacturers' overly broad patent descriptions, which can otherwise delay affordable generics from reaching pharmacy shelves for years. Patients and insurers who rely on lower-cost generics benefit from faster market entry, while brand manufacturers face more scrutiny over how they describe their patents to the FDA.
What changes now
The case returns to the lower courts, where Caraco may now pursue its counterclaim to force Novo to correct its use code, potentially clearing the way for Caraco's generic drug application to proceed under the carve-out labeling option. This is a final merits decision resolving the legal question, though the underlying patent dispute and any remaining factual issues continue in the lower courts.
What this does not decide
The Court did not decide whether the FDA's own hands-off approach to verifying use codes is lawful, nor did it resolve the parties' underlying patent dispute; on remand, a district court had separately found the patent invalid, a ruling not addressed by this decision.
Concurrences and dissents
Concurrence — Justice Sotomayor
“A fix is in order, but it must come from Congress or FDA.”Sotomayor's view that the counterclaim only partly solves the problem of overly broad use codes.
Justice Sotomayor joined the Court's opinion but emphasized that the counterclaim only partially fixes the problem: a generic company must still first file a paragraph IV certification, get sued, and litigate the counterclaim before it can pursue the section viii pathway it wanted all along, causing delay and expense the statute did not intend. She also criticized the FDA's guidance on use codes as remarkably unclear, contributing to disputes like this one, and said a full fix requires action from Congress or the FDA.
How the Court got there
The legal reasoning, step by step
- The Court first examined the phrase letting a generic company sue when a patent 'does not claim ... an approved method of using the drug,' asking whether 'not an' means 'not any' (no approved use at all) or 'not a particular one' (not this specific use). Because English usage of 'not an' shifts depending on context, the Court looked to the surrounding statutory scheme rather than dictionary definitions.
- Since the law lets the FDA approve a generic drug for any unpatented use even if another use remains patented, the Court reasoned that the challenge should be available whenever the patent fails to cover the specific use the generic company wants to sell, not only when the patent covers no use whatsoever.
- The Court then decided whether a 'use code' -- the brand's description of what its patent covers -- counts as 'patent information submitted under' the statute's information-filing subsections, even though those subsections only expressly mention patent numbers and expiration dates. The Court read the word 'under' broadly, following its precedents interpreting similar language, to include filings required by regulations issued pursuant to those subsections, not just filings the statute itself lists by name.
- The Court reinforced this reading by noting the statute allows a successful challenge to result in either 'deleting' or 'correcting' a patent listing; if the challenge could only succeed where a patent covers no use at all, or if use codes were excluded, the word 'correct' would have no real function, and courts avoid readings that make part of a statute meaningless.
- The Court rejected the brand manufacturer's argument based on a failed earlier bill and a prior court decision involving a different kind of patent-listing error, concluding that the enacted law was written broadly enough to address inaccurate use codes, not just baseless patent listings entirely.
Doctrinal impact
Cases affected by this decision
Distinguishes Mylan Pharmaceuticals, Inc. v. Thompson (268 F. 3d 1323)
The Court said this case addressed only baseless patent listings, not the broader problem of overbroad but partially valid use codes.
Reaffirms Eli Lilly & Co. v. Medtronic, Inc. (496 U. S. 661)
The Court relied on this decision's broad reading of the word 'under' to interpret the counterclaim's scope.